Click 'Accept all cookies' to agree to all cookies that collect anonymous data.
To only allow the cookies that make the site work, click 'Use essential cookies only.' Visit 'Set cookie preferences' to control specific cookies.
Note that this page is no longer being updated for Covid therapeutic alerts. From December 2022 you will find the most up to date information on the SHOW site. Search using the keywords: Covid therapeutic alert.
Covid therapeutic alert - interleukin-6 (IL-6) inhibitors (tocilizumab (RoActemra) or sarilumab (Kevzara)) to adult patients hospitalised due to COVID-19: alert (PDF) and database entry
Covid therapeutic alert – recommendation for the immediate commencement of the palivizumab passive immunisation programme: alert (PDF) and database entry
Covid therapeutic alert – palivizumab passive immunisation against respiratory syncytial virus (RSV) in at risk pre-term infants: alert (PDF) and database entry
Covid therapeutic alert – antivirals and neutralising monoclonal antibodies in the treatment of Covid-19 in non-hospitalised patients: alert (PDF) and database entry
Covid therapeutic alert – antivirals and neutralising monoclonal antibodies in the treatment of Covid-19 in hospitalised patients: alert (PDF) and database entry
update to interim clinical commissioning policy on the use of neutralising monoclonal antibody and intravenous antiviral treatments for non-hospitalised patient with Covid infection: alert (PDF) and database entry
neutralising monoclonal antibody and intravenous antiviral treatments for patients in hospital with covid infection: alert (PDF) and database entry
interim clinical commissioning policy regarding the use of neutralising monoclonal antibodies or antivirals for patients with COVID-19 (16 December 2021):
updated UK rapid policy statement circular and database, which extends eligibility for palivizumab beyond the guidance issued by the Joint Committee on Vaccination and Immunisation (JCVI), specifically in the context of the COVID-19 pandemic, which has now been updated to accommodate the atypical current seasonal pattern of infection and increase the maximum number of doses from five to seven (July 2021) circular
update to the National Institute for Health and Care Excellence (NICE) rapid guideline recommending the consideration of continuous positive airway pressure (CPAP), alongside optimised pharmacological and non-pharmacological management strategies (including body positioning), in patients hospitalised with COVID-19. Read the letter and database entry
combined policy replacing previous separately published policies for sarilumab and tocilizumab respectively on 17 February 2021. A single UK Interim Clinical Commissioning Policy has now been published, recommending that equal consideration is given to two potential interleukin-6 (IL-6) inhibitor treatment options - tocilizumab or sarilumab - for adult patients (aged 18 years and older) hospitalised due to COVID-19 in accordance with the agreed criteria. Read the letter and database entry
the recommendations contained in the UK-wide clinical commissioning published on 17 September 2021 have been revised to include the use of casirivimab and imdevimab in the treatment of COVID-19 in hospital patients to include the use of this intravenous combination in patients aged 12 years and over. Read the alert and database entry
granting of a conditional marketing authorisation on 4 November 2021, by the Medicines and Healthcare products Regulatory Agency (MHRA) for the first oral antiviral for COVID-19, molnupiravir (brand name: Lagevrio). Read the letter and database entry.